Outlook Therapeutics, Inc.
OTLK
$1.25
$0.119.65%
| Weiss Ratings | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.08 | |||
| Price History | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.30% | |||
| 30-Day Total Return | -15.54% | |||
| 60-Day Total Return | -47.26% | |||
| 90-Day Total Return | -74.65% | |||
| Year to Date Total Return | -39.32% | |||
| 1-Year Total Return | -86.63% | |||
| 2-Year Total Return | -93.99% | |||
| 3-Year Total Return | -96.60% | |||
| 5-Year Total Return | -89.40% | |||
| 52-Week High % Change | -88.58% | |||
| 52-Week Low % Change | 31.03% | |||
| Price | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.98 | |||
| 52-Week Low Price | $0.87 | |||
| 52-Week Low Price (Date) | Nov 27, 2024 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 36.50M | |||
| Enterprise Value | 61.83M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -7.94 | |||
| Earnings Per Share Growth | 99.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.56 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.25 | |||
| Enterprise Value/EBITDA (TTM) | -0.75 | |||
| Enterprise Value/EBIT | -0.75 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 24.23M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 609 619 3990 | |||
| Address | 111 S. Wood Avenue Iselin, NJ 08830 | |||
| Website | www.outlooktherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -268.11% | |||
| Return on Equity | -- | |||
| Income Statement | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -33.39M | |||
| EBITDA (TTM) | -82.87M | |||
| EBIT (TTM) | -82.99M | |||
| Net Income (TTM) | -46.81M | |||
| Net Income Avl. to Common (TTM) | -46.81M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 255.46% | |||
| EPS Diluted (TTM) | -7.94 | |||
| EPS Diluted Growth (Q YOY) | 183.38% | |||
| Balance Sheet | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.70M | |||
| Cash Per Share (Q) | $0.24 | |||
| Total Current Assets (Q) | 15.67M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -50.29M | |||
| Current Ratio (Q) | 0.325 | |||
| Book Value Per Share (Q) | -$2.02 | |||
| Total Assets (Q) | 17.01M | |||
| Total Current Liabilities (Q) | 48.24M | |||
| Total Debt (Q) | 31.03M | |||
| Total Liabilities (Q) | 67.30M | |||
| Total Common Equity (Q) | -50.29M | |||
| Cash Flow | OTLK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 62.07M | |||
| Net Change in Cash (TTM) | -4.65M | |||
| Levered Free Cash Flow (TTM) | -37.81M | |||
| Cash from Operations (TTM) | -66.73M | |||
